scholarly journals Identification of metastasis in the skeleton bones in patients with breast and prostate cancer: markers of bone metabolism and MRI diagnostics

2020 ◽  
pp. 19-25
Author(s):  
N. Safonov ◽  
O. Drobotun ◽  
E. Tuz ◽  
V. Vovk ◽  
N. Kolotilov
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Resorption ◽  
Blood Serum ◽  
Bone Metabolism ◽  
Predictive Value ◽  
Tumor Regression ◽  
Radical Mastectomy ◽  
Tartrate Resistant Acid Phosphatase ◽  
Markers Of Bone Resorption

The purpose of the investigation is to study biochemical markers of bone metabolism in patients with breast cancer and prostate cancer during periods of stable remission and recurrence/metastasis and to assess their informative value in the diagnosis and monitoring of skeletal lesions. The study included 21 female patients with breast cancer and 18 male patients with prostate cancer. The start of monitoring is at least 3 years after complete tumor regression as a result of treatment: breast cancer – radical mastectomy, prostate cancer – radical prostatectomy. Markers of bone resorption (urine deoxypyridinoline, C-terminal telopeptide and tartrate-resistant acid phosphatase of blood serum) and osteogenesis (bone alkaline phosphatase and osteocalcin of blood serum) in patients with breast cancer and prostate cancer can be used for early diagnosis of metastasis in the skeleton bones: changes in indicators are observed 6-10 months before the first radiological/ MRI signs appear. The application of simultaneously used markers of bone resorption and osteogenesis in patients with breast cancer and prostate cancer provides a sensitivity of 89.7 %, a specificity of 84.5 %, a positive predictive value of 82.6 % and a negative predictive value of 95.3 %.

Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease

1995 ◽  
Vol 41 (11) ◽  
pp. 1592-1598 ◽  
Author(s):  
A Blumsohn ◽  
K E Naylor ◽  
A M Assiri ◽  
R Eastell
Keyword(s):  
Bone Resorption ◽  
Biochemical Markers ◽  
Type I Collagen ◽  
Bisphosphonate Therapy ◽  
Response To Therapy ◽  
Tartrate Resistant Acid Phosphatase ◽  
Type I ◽  
Paget Disease ◽  
Markers Of Bone Resorption ◽  
Total Alkaline

Abstract We examined the response of different biochemical markers of bone resorption to bisphosphonate therapy (400 mg of etidronate daily for 6 months) in mild Paget disease (n = 14). Urinary markers included hydroxyproline (OHP), total (T) and free (F) pyridinolines (Pyds) determined by HPLC, immunoreactive FPyds, immunoreactive TPyds, and the N- and C-terminal telopeptides of type I collage (NTx, CL). Serum measurements included tartrate-resistant acid phosphatase (TRAcP) and the C-terminal telopeptide of type I collagen (ICTP). ICTP and TRAcP showed a minimal response to therapy (% change at 6 months, -13.1 +/- 6.8 and -6.7 +/- 3.4, respectively). The response was greatest for urinary telopeptides (NTx and CL; % change -75.7 +/- 7.5 and -73.4 +/- 8.9, respectively). The response was somewhat greater for TPyds than for FPyds. We conclude that: (a) ICTP and TRAcP are unreliable indicators of changes in bone turnover; (b) oligopeptide-bound Pyds and telopeptide fragments of type I collagen in urine show a somewhat greater response to therapy than do FPyds and may be more sensitive indicators of bone resorption; and (c) as yet no evidence suggests that these markers are substantially better predictors of the clinical response to therapy than serum total alkaline phosphatase or urinary OHP. There are several problems with the interpretation of these measurements in Paget disease, and the clinical utility of these measurements remains uncertain.

Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer

2004 ◽  
Vol 138 (7) ◽  
pp. 77-79 ◽  
Author(s):  
N. V. Lyubimova ◽  
M. V. Pashkov ◽  
S. A. Tyulyandin ◽  
V. E. Gol’dberg ◽  
N. E. Kushlinskii
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Bone Metastases ◽  
Tartrate Resistant Acid Phosphatase

Biochemical markers of bone resorption are present in human milk: implications for maternal and neonatal bone metabolism

2014 ◽  
Vol 103 (12) ◽  
pp. 1264-1269 ◽  
Author(s):  
Maria Bouroutzoglou ◽  
Ariadne Malamitsi-Puchner ◽  
Maria Boutsikou ◽  
Antonios Marmarinos ◽  
Stavroula Baka ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Human Milk ◽  
Bone Metabolism ◽  
Biochemical Markers ◽  
Markers Of Bone Resorption

scholarly journals Metachronous or synchronous male breast and prostate cancers a duality to lookout for.

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1825
Author(s):  
Alain Mwamba Mukendi ◽  
Eunice Van Den Berg ◽  
Sugeshnee Pather ◽  
Rushen Siva Padayachee
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Bone Scan ◽  
Digital Rectal Examination ◽  
Radical Mastectomy ◽  
Modified Radical Mastectomy ◽  
Breast Lump ◽  
History Of ◽  
Prostate Cancers

Introduction: Breast cancer is well known as the stereotypical women's cancer, and prostate cancer represents the well-known stereotypical male counterpart. While prostate cancer carries the potential to metastasize to the breast, the synchronous or metachronous co-occurrence of primary breast and primary prostate cancers is quite unusual. Prostate cancer in men of African descent may have its own behavior with regards to its relationship with male breast cancer. Case presentation: Case 1: A 64 year old male presented to Chris Hani Baragwanath Hospital (CHBAH) with a 2 years history of a painless left breast lump. A core biopsy was confirmed breast carcinoma. Tamoxifen was started but, due to disease progression, he underwent left modified radical mastectomy followed by chemotherapy. Prostate biopsy was done for raised Prostate Specific Antigen (PSA) and suspicious prostate on digital rectal examination. A prostatic adenocarcinoma was subsequently diagnosed with bone metastasis on bone scan. He was started on Androgen deprivation therapy and followed up every 3 months. Case 2: A 68 year old male presented to CHBAH with a 1 year history of a painless right breast lump. A core biopsy confirmed breast cancer. Tamoxifen was started, followed by right modified radical mastectomy and chemotherapy for disease progression. A raised PSA and suspicious prostate on digital rectal examination prompted a prostate biopsy revealing a prostatic adenocarcinoma. Bone scan was negative for metastasis. He is currently on 3 monthly Androgen deprivation therapy and awaiting radiation. Conclusion: This clinical practice article not only presents this exceptionally rare duality but highlights that both cancers can coexist either as sporadic conditions, or as a result of genetic mutations. Thus, we suggest that men with prostate cancer be screened clinically, biochemically and genetically for breast cancer and vice versa.

scholarly journals Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers

2011 ◽  
Vol 3 ◽  
pp. BIC.S6484 ◽  
Author(s):  
D.J. Leeming ◽  
M. Koizumi ◽  
P. Qvist ◽  
V. Barkholt ◽  
C. Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Collagen Type ◽  
Collagen Type I ◽  
Tartrate Resistant Acid Phosphatase ◽  
Type I ◽  
Breast And Prostate Cancer

Background A number of biomarkers have been proven potentially useful for their ability to indicate bone metastases (BM) in cancer patients. The aim of this study was to investigate the relative utility of a newly developed N-terminal propeptide of collagen type I (PINP) human serum assay for the detection of BM in cancer patients. This assay has a corresponding rat PINP assay which in the future might help in translational science between rodent and human trials. Methods Participants were 161 prostate, lung and breast cancer patients stratified by number of BM(Soloway score). PINP was assessed and correlated to number of BM. Additionally, the PINP marker was correlated to bone resorption of young (ALPHA CTX-I)- and aged bone (BETA CTX-I); number of osteoclasts (Tartrate-resistant acid phosphatase 5b, TRACP5B) and osteoclast activity (CTX-I/TRACP5B). Results PINP was significantly elevated in breast- and prostate cancer patients +BM, compared to –BM ( P < 0.001), however not in lung cancer patients. A strong linear association was seen between PINP and the number of BMs. Significant elevation of PINP was observed at Soloway scores 1–4 (<0 BM) compared with score 0 (0 BM) ( P < 0.001). The correlation between bone resorption of young bone or aged bone and bone formation was highly significant in patients +BM and –BM ( P < 0.0001). Conclusions Data suggest that the present PINP potentially could determine skeletal involvement in patients with breast or prostate cancer. Correlations suggested that coupling between bone resorption and bone formation was maintained in breast- and prostate cancer patients.

Sign in / Sign up

Export Citation Format

Share Document